search
Back to results

Breast Cancer Exercise Intervention Study (BREXINT)

Primary Purpose

Early-stage Breast Cancer, Locally Advanced Breast Cancer

Status
Recruiting
Phase
Not Applicable
Locations
Singapore
Study Type
Interventional
Intervention
Exercise Programme
Control
Sponsored by
National Cancer Centre, Singapore
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Early-stage Breast Cancer focused on measuring BREXINT, Muscular Strength, Cardiorespiratory Fitness, Quality of Life

Eligibility Criteria

21 Years - 99 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Patients with histologically or cytologically proven stage 1, 2, or 3 breast cancer Patients who have undergone curative breast surgery Patients who have received (neo)adjuvant chemotherapy (if given) and/or radiotherapy (if given) Females aged 21 years and older ≤ 8 weeks from breast surgery, or the last adjuvant chemotherapy or radiotherapy session, whichever is latest. Exclusion Criteria: Cardiovascular, respiratory, musculoskeletal problems that preclude moderate physical activity. Major medical problems that are deemed by the investigator to be unsuitable for enrollment.

Sites / Locations

  • National University HospitalRecruiting
  • National Cancer CentreRecruiting
  • Singapore General HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Exercise

Control

Arm Description

The exercise intervention group will undergo an aerobic exercise and strength training programme, comprising 3 sessions per week, spanning 24 weeks (total: 3x24=72 sessions).

The usual care group.

Outcomes

Primary Outcome Measures

Disease-Free Survival (DFS)
From the date of randomization to when an event, i.e. relapse, has occurred.

Secondary Outcome Measures

Overall Survival (OS)
From the date of randomization to when an event, i.e. death, has occurred.

Full Information

First Posted
June 13, 2023
Last Updated
July 19, 2023
Sponsor
National Cancer Centre, Singapore
Collaborators
Singapore Cancer Society, Genome Institute of Singapore, National University of Singapore, Singapore General Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05957068
Brief Title
Breast Cancer Exercise Intervention Study
Acronym
BREXINT
Official Title
Breast Cancer Exercise Intervention Study (BREXINT)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 1, 2023 (Actual)
Primary Completion Date
May 31, 2028 (Anticipated)
Study Completion Date
May 31, 2033 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Cancer Centre, Singapore
Collaborators
Singapore Cancer Society, Genome Institute of Singapore, National University of Singapore, Singapore General Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a 24-week exercise programme consisting of aerobic exercise and muscle strength training, 3 sessions per week. The first 9 sessions are supervised by physiotherapists in person, followed by 63 sessions monitored remotely (video) or supervised by trainers at ActiveSG (Sport Singapore) gyms.
Detailed Description
This is a multi-centre, randomised controlled study of a 6-month (24-week) exercise programme versus observation in 2156 early stage and locally advanced breast cancer patients who have undergone curative breast surgery, and who have completed (neo)adjuvant chemotherapy (if given) or radiotherapy (if given). Patients are stratified by centre (NCC/SGH, NUH), menopausal status, ER/PR status, body fat/muscle ratio. Cardiorespiratory fitness, muscle strength, level of routine daily physical activity, body fat/muscle ratio are monitored during the study period. Blood is collected at baseline, 8 weeks, 16 weeks, 24 weeks, 52 weeks, then annually for 4 times. Questionnaires are periodically conducted to assess quality of life (QoL). A food diary is kept.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Early-stage Breast Cancer, Locally Advanced Breast Cancer
Keywords
BREXINT, Muscular Strength, Cardiorespiratory Fitness, Quality of Life

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Eligible patients will be randomised into 2 groups: exercise (intervention group, N = 1078) and usual care (control group, N = 1078). The exercise intervention group will undergo an aerobic exercise and strength training programme.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
2156 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Exercise
Arm Type
Experimental
Arm Description
The exercise intervention group will undergo an aerobic exercise and strength training programme, comprising 3 sessions per week, spanning 24 weeks (total: 3x24=72 sessions).
Arm Title
Control
Arm Type
Experimental
Arm Description
The usual care group.
Intervention Type
Behavioral
Intervention Name(s)
Exercise Programme
Intervention Description
Aerobic exercise consists of 20-minute brisk walks or jogs (5-6 km/h) on the treadmill each session, reaching a heart rate corresponding to 50%-70% of the patient's VO2max (VO2max is determined before embarking on the exercise programme). Study participants are expected to aim for 50% VO2max at the start of the exercise programme, and gradually increasing to 70% VO2max in subsequent exercise sessions. Strength training comprises a series of circuit resistance exercises targeting the major muscle groups. Patients will perform 2-4 sets of these exercises each session, 8-10 repetitions per set. Both aerobic exercise and strength training are done in the same session. With warm-up and cool-down, each session is estimated to take up 1 hour.
Intervention Type
Behavioral
Intervention Name(s)
Control
Intervention Description
Usual care group.
Primary Outcome Measure Information:
Title
Disease-Free Survival (DFS)
Description
From the date of randomization to when an event, i.e. relapse, has occurred.
Time Frame
Up to 5 years.
Secondary Outcome Measure Information:
Title
Overall Survival (OS)
Description
From the date of randomization to when an event, i.e. death, has occurred.
Time Frame
Up to 5 years.
Other Pre-specified Outcome Measures:
Title
Body fat/muscle ratio.
Description
Body fat mass (in grams) divided by body muscle mass (in grams).
Time Frame
Week 0, Week 8, Week 16 and Week 24.
Title
Changes in absolute and relative VO2.
Description
Changes in absolute (L/min) and relative VO2 (mL/kg/min) at 8, 16 and 24 weeks from baseline.
Time Frame
Week 8, Week 16 and Week 24.
Title
Changes in heart rate at rest and during CPET.
Description
Changes in heart rate (HR, beats/min) at rest and during CPET, at 8, 16 and 24 weeks from baseline.
Time Frame
Week 8, Week 16 and Week 24.
Title
Changes in oxygen pulse (VO2/HR) during CPET.
Description
Changes in oxygen pulse (VO2/HR) during CPET, at 8, 16, and 24 weeks from baseline.
Time Frame
Week 8, Week 16 and Week 24.
Title
Changes in respiratory exchange ratio (RER) during CPET.
Description
Changes in respiratory exchange ratio (RER, unitless) during CPET, at 8, 16, and 24 weeks from baseline
Time Frame
Week 8, Week 16 and Week 24.
Title
Changes in weight lifted 10 repetition maximum.
Description
Changes in weight lifted 10 repetition maximum (10-RM, Kg) for: a. Chest press; b. Latissimus pull-down; c. 2-arm curl; and d. Leg press.
Time Frame
Week 0, Week 8, Week 16 and Week 24.
Title
Changes in absolute fat mass and relative fat mass from baseline.
Description
Changes in absolute fat mass (kg) and relative fat mass (%) at 8, 16, and 24 weeks from baseline.
Time Frame
Week 8, Week 16 and Week 24.
Title
Changes in absolute lean mass and relative lean mass from baseline.
Description
Changes in absolute lean mass (kg) and relative lean mass (%) at 8, 16, and 24 weeks from baseline.
Time Frame
Week 8, Week 16 and Week 24.
Title
Changes in absolute and relative bone mineral density (BMD) at 8, 16, and 24 weeks from baseline.
Description
Changes in absolute and relative bone mineral density (BMD, in g/cm^2) at 8, 16, and 24 weeks from baseline.
Time Frame
Week 8, Week 16 and Week 24.

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with histologically or cytologically proven stage 1, 2, or 3 breast cancer Patients who have undergone curative breast surgery Patients who have received (neo)adjuvant chemotherapy (if given) and/or radiotherapy (if given) Females aged 21 years and older ≤ 8 weeks from breast surgery, or the last adjuvant chemotherapy or radiotherapy session, whichever is latest. Exclusion Criteria: Cardiovascular, respiratory, musculoskeletal problems that preclude moderate physical activity. Major medical problems that are deemed by the investigator to be unsuitable for enrollment.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dr Elaine LIM, MD, PhD
Phone
+65 64368000
Email
elaine.lim.hsuen@singhealth.com.sg
First Name & Middle Initial & Last Name or Official Title & Degree
Catherine CELES
Email
catherine.celes@nccs.com.sg
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dr Elaine LIM, MD, PhD
Organizational Affiliation
National Cancer Centre, Singapore
Official's Role
Principal Investigator
Facility Information:
Facility Name
National University Hospital
City
Singapore
ZIP/Postal Code
119074
Country
Singapore
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Professor Soo Chin LEE, MD
Phone
+65 67737888
Email
ncis@nuhs.edu.sg
Facility Name
National Cancer Centre
City
Singapore
ZIP/Postal Code
168583
Country
Singapore
Individual Site Status
Recruiting
Facility Name
Singapore General Hospital
City
Singapore
ZIP/Postal Code
169608
Country
Singapore
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr Veronique TAN, MD
Phone
+65 62223322
Email
veronique.tan.k.m@singhealth.com.sg

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Once data is available, only de-identified IPD will be shared to collaborators.

Learn more about this trial

Breast Cancer Exercise Intervention Study

We'll reach out to this number within 24 hrs